Andrew Crabbe
A5037110774- Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Galectins and Cancer Biology
- CAR-T cell therapy research
- Colorectal Cancer Surgical Treatments
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematological disorders and diagnostics
- Acute Myeloid Leukemia Research
- Colorectal and Anal Carcinomas
- Immune Cell Function and Interaction
Massachusetts General Hospital
2021-2024
Akron General Medical Center
2022-2024
Cleveland Clinic
2022-2024
Abstract Purpose: Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms. Experimental Design: Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation. Results: Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma (ENKTCL), T-prolymphocytic leukemia (T-PLL),...
Micropapillary carcinoma (MPC) is a recognised WHO variant of colonic (CC), although little known about its prognosis, immune microenvironment and molecular alterations. We investigated clinical, pathological immunological characteristics.
Serrated adenocarcinoma (SAC), a recognised WHO variant of colonic adenocarcinoma, is the purported end-product serrated neoplasia. However, diagnosis SAC infrequently rendered, and little known about its prognosis, immune microenvironment molecular alterations.We assessed 903 consecutive colon carcinomas tumours with ≥ 5% (n = 77) 50% patterns 13). We precursor polyps synchronous polyps. recorded demographic/clinical parameters, histological features mismatch repair (MMR) status. performed...
<p>Supplementary Methods and Figures</p>
<p>Supplementary Methods and Figures</p>
<div>AbstractPurpose:<p>Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms.</p>Experimental Design:<p>Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation.</p>Results:<p>Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma...
<div>AbstractPurpose:<p>Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms.</p>Experimental Design:<p>Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation.</p>Results:<p>Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma...
A 49-year-old man was evaluated because of relapsed acute myeloid leukemia that occurred 14 months after the initial diagnosis and treatment. Molecular genetic profiling at time relapse identified a new internal tandem duplication mutation in FLT3 (FLT3-ITD). bone marrow biopsy performed, management decisions were made.